Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Shares of Oncolytics Biotech Inc. (TSE:ONC) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$8.16 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.

Analyst Ratings Changes

Separately, Lake Street Capital raised shares of Oncolytics Biotech to a “strong-buy” rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Oncolytics Biotech Stock Down 1.3%

The company has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The company has a fifty day moving average of C$14.90 and a two-hundred day moving average of C$8.16. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. As a group, analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.